第一三共（4568） – Daiichi Sankyo Announces Changes to Representative Directors, Directors, and Audit & Supervisory Board Members

Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Sunao Manabe, Representative Director, President and CEO (Code no.: 4568, Prime Market, Tokyo Stock Exchange) Please address inquiries to Kentaro Asakura, Vice President, Corporate Communications Department Telephone: +81-3-6225-1126 https://www.daiichisankyo.com Daiichi Sankyo Announces Changes to Representative Directors, Directors, and Audit & Supervisory Board Members Tokyo, Japan – (May 19, 2022) – Daiichi Sankyo Company, Limited (hereinafter, the Company) today announced that its Board of Directors has approved changes to its Representative Directors, Directors, and Audit & Supervisory Board Members as follows. Appointments will be subject to approval at the Company’s 17th Annual General Meeting of Shareholders on June 27 and formal resolutions at a subsequent board meeting. 1. Changes to Representative Directors (as of June 27, 2022) Reason for change: Expiration of Representative Director’s term (1) Appointed Representative Director Name Current Position New Position Shoji Hirashima Director Senior Executive Officer Head of Japan Business Unit Representative Director Senior Executive Officer Head of Japan Business Unit (2) Retiring Representative Director Name Current Position New Position Satoru Kimura Representative Director Senior Adviser 2. Changes to Directors (as of June 27, 2022) (1) New candidates for Directors Name Current Position Takashi Fukuoka Executive Officer, Head of Corporate Strategy Div. Yasuhiro Komatsu Chairman and Professor, Department of Healthcare Quality and Safety, Graduate School of Medicine, Gunma University Director, Department of Healthcare Quality and Safety, Gunma University Hospital Vice president (specially appointed), Gunma University Hospital) * Yasuhiro Komatsu is a new candidate for Outside Director as defined in Article 2-15 of the Companies Act. 1 (2) Retiring Directors Name Current Position Satoru Kimura Representative Director Tsuguya Fukui Outside Director * Satoru Kimura will be appointed as a Senior Adviser. 3. Changes to Audit & Supervisory Board Members (as of June 27, 2022) (1) Candidates for Outside Audit & Supervisory Board Members Name Current Position Yukiko Imazu Outside Audit & Supervisory Board Member Mitsuhiro Matsumoto (Former Commissioner-General of the National Police Agency) * Yukiko Imazu and Mitsuhiro Matsumoto are candidates for Outside Audit & Supervisory Board Member as defined in Article 2-16 of the Companies Act. (2) Retiring Outside Audit & Supervisory Board Member Name Current Position Tateshi Higuchi Outside Audit & Supervisory Board Member 2 Attachment Curriculum Vitae 1. Appointed Representative Director Shoji Hirashima: Born March 6, 1961 Current Position Held Director, Senior Executive Officer, Head of Japan Business Unit, Daiichi Sankyo Co., Ltd. Career Summary Apr. 1988 Joined Daiichi Pharmaceutical Company, Limited Apr. 2010 CEO, U3 Pharma GmbH Apr. 2015 Vice President, Corporate Strategy Department, Corporate Strategy Division of the Company Apr. 2016 Vice President of Corporate Strategy Department and Senior Director of Oncology Business Group, Corporate Strategy Division of the Company Apr. 2017 Corporate Officer, Vice President of Corporate Business Management Department, Corporate Strategy and Management Division Apr. 2019 Executive Officer, Head of Global Brand Strategy Division of the Company Apr. 2020 Senior Executive Officer, Head of Global Brand Strategy Division of the Company Jun. 2020 Director, Senior Executive Officer, Head of Global Brand Strategy Division of the Company Apr. 2021 Director, Senior Executive Officer, Head of Corporate Strategy Division of the Company Apr. 2022 Director, Senior Executive Officer, Head of Japan Business Unit of the Company (to present) The number of shares of the Company Held: 64,090 3 2. Candidate for Director Takashi Fukuoka: Born April 27, 1961 Current Position Held Career Summary Apr. 1987 Joined Sankyo Company, Limited Executive Officer, Head of Corporate Strategy Div., Daiichi Sankyo Co., Ltd. Apr. 2013 Vice President of Venture Science Laboratories, R&D Division of the Company Apr. 2019 Corporate Officer, Executive Vice President, R&D Affairs, Daiichi Sankyo, Inc. Apr. 2022 Executive Officer, Head of Corporate Strategy Division of the Company (to present) Yasuhiro Komatsu: Born October 25, 1957 Current Position Held Chairman and Professor, Department of Healthcare Quality and Safety, Graduate School of Medicine, Gunma University Director, Department of Healthcare Quality and Safety, Gunma University Hospital Vice president (specially appointed), Gunma University Hospital Career Summary Aug. 1998 Chief, Department of nephrology, St. Luke’s International Hospital Nov. 2007 Director, Kidney center. St. Luke’s International Hospital Jan. 2011 Vice President, Chief Quality and Safety Officer, St. Luke’s International Hospital Nov. 2017 Chairman and Professor, Department of Healthcare Quality and Safety, Graduate School of Medicine, Gunma University (to present) Nov. 2017 Director, Department of Healthcare Quality and Safety, Gunma University Hospital (to present) Apr. 2018 Vice president (specially appointed), Gunma University Hospital (to present) 4 3. Candidate for Outside Audit & Supervisory Board Member Yukiko Imazu: Born July 28, 1968 Current Position Held Partner, Attorney-at-Law, Anderson Mōri & Tomotsune Career Summary Apr. 1996 Joined Anderson Mōri (currently, Anderson Mōri & Tomotsune) Jan. 2005 Partner, Attorney-at-Law, Anderson Mōri & Tomotsune (to present) Apr. 2007 Associate Professor, Keio University Law School Mar. 2014 Director of Ishibashi Foundation (to present) Jun. 2018 Outside Audit & Supervisory Board Member of the Company (to present) Mitsuhiro Matsumoto: Born March 21, 1961 Former Position Held Commissioner-General, the National Police Agency Career Summary Apr. 1983 Joined the National Police Agency (NPA) Oct. 2009 Chief, Fukushima Prefectural Police Apr. 2012 Director, Personnel Division, Commissioner-General’s Secretariat, NPA Apr. 2013 Director-General, Public Security Department, Tokyo Metropolitan Police Apr. 2014 Chief, Kanagawa Prefectural Police Aug. 2015 Director-General, Foreign Affairs and Intelligence Department, NPA Sep. 2016 Director-General, Security Bureau, NPA Jan. 2018 Director-General, Commissioner-General’s Secretariat, NPA Sep. 2018 Deputy Commissioner-General, NPA Jan. 2020 Commissioner-General, NPA Sep. 2021 Retired from NPA 5 For Reference: Directors and Audit & Supervisory Board Members after the election at the Ordinary General Meeting of Shareholders (as of June 27, 2022) Name Positions and Assignments Sunao Manabe Representative Director, President and CEO Shoji Hirashima Representative Director, Senior Executive Officer, Head of Japan Business Unit Masahiko Ohtsuki Director, Senior Executive Officer, Head of Digital Transformation Management Div. Hiroyuki Okuzawa Director, Senior Executive Officer, Head of Corporate Planning & Management Div., CFO Takashi Fukuoka Director, Executive Officer, Head of Corporate Strategy Div. Noritaka Uji Outside Director Kazuaki Kama Outside Director Sawako Nohara Outside Director Yasuhiro Komatsu Outside Director Ryoichi Watanabe Audit & Supervisory Board Member Kenji Sato Audit & Supervisory Board Member Yukiko Imazu Outside Audit & Supervisory Board Member Masako Watanabe Outside Audit & Supervisory Board Member Mitsuhiro Matsumoto Outside Audit & Supervisory Board Member 6 About Daiichi Sankyo Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.” For more information, please visit www.daiichisankyo.com. Media Contacts: Japan: Masashi Kawase Daiichi Sankyo Co., Ltd. kawase.masashi.a2@daiichisankyo.co.jp +81 3 6225 1126 (office) Investor Relations Contact: DaiichiSankyoIR@daiichisankyo.co.jp 7